Valneva SE Cash Flow Conversion Efficiency
Valneva SE cash flow conversion efficiency. Based on the latest financial reports, Valneva SE (VLA) has a cash flow conversion efficiency ratio of -0.223x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-18.06 Million ≈ $-21.11 Million USD) by net assets (€81.12 Million ≈ $94.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Valneva SE (2005–2025)
Cash flow conversion efficiency of Valneva SE from 2005 to 2025. This chart illustrates how Valneva SE's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Valneva SE stock quote for real-time trading data and today's change.
Valneva SE Cash Flow Conversion Ratio Explained
Valneva SE cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Valneva SE Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Valneva SE ranked by their cash flow conversion efficiency. Also see Valneva SE market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Feymer Technology Co Ltd
SHG:688350
|
0.064x |
|
SAPPI LTD ADR/1 RC 1
F:SPIA
|
0.023x |
|
GKHT Medical Technology Co. Ltd. A
SHE:301370
|
N/A |
|
JiangSu JiangHuai Engine Co Ltd
SHE:000816
|
0.007x |
|
Jinneng Science&Tech Co Ltd
SHG:603113
|
-0.049x |
|
Taiwan Sakura Corp
TW:9911
|
0.059x |
|
Bestlink Tech Co Ltd
SHG:603206
|
-0.067x |
|
ABBISKO CAYMAN DL-00001
F:8ZD
|
N/A |
Annual Cash Flow Conversion Efficiency for Valneva SE (2005–2025)
The table below shows the annual cash flow conversion efficiency of Valneva SE from 2005 to 2025. Review Valneva SE (VLA) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €106.17 Million ≈ $124.12 Million |
€-52.89 Million ≈ $-61.84 Million |
-0.498x | -34.34% |
| 2024-12-31 | €181.25 Million ≈ $211.90 Million |
€-67.22 Million ≈ $-78.58 Million |
-0.371x | +76.54% |
| 2023-12-31 | €128.25 Million ≈ $149.93 Million |
€-202.74 Million ≈ $-237.03 Million |
-1.581x | -41.63% |
| 2022-12-31 | €219.80 Million ≈ $256.97 Million |
€-245.34 Million ≈ $-286.83 Million |
-1.116x | -347.60% |
| 2021-12-31 | €170.58 Million ≈ $199.43 Million |
€76.90 Million ≈ $89.91 Million |
0.451x | -74.66% |
| 2020-12-31 | €77.42 Million ≈ $90.51 Million |
€137.74 Million ≈ $161.03 Million |
1.779x | +4248.79% |
| 2019-12-31 | €135.15 Million ≈ $158.01 Million |
€5.53 Million ≈ $6.46 Million |
0.041x | -64.08% |
| 2018-12-31 | €143.19 Million ≈ $167.40 Million |
€16.31 Million ≈ $19.06 Million |
0.114x | -17.74% |
| 2017-12-31 | €92.67 Million ≈ $108.34 Million |
€12.83 Million ≈ $15.00 Million |
0.138x | +112.93% |
| 2016-12-31 | €100.05 Million ≈ $116.97 Million |
€6.50 Million ≈ $7.61 Million |
0.065x | +138.56% |
| 2015-12-31 | €144.34 Million ≈ $168.74 Million |
€-24.33 Million ≈ $-28.45 Million |
-0.169x | -40.39% |
| 2014-12-31 | €124.44 Million ≈ $145.49 Million |
€-14.94 Million ≈ $-17.47 Million |
-0.120x | +17.21% |
| 2013-12-31 | €144.11 Million ≈ $168.48 Million |
€-20.90 Million ≈ $-24.44 Million |
-0.145x | +71.26% |
| 2012-12-31 | €26.19 Million ≈ $30.62 Million |
€-13.22 Million ≈ $-15.46 Million |
-0.505x | -135.82% |
| 2011-12-31 | €40.45 Million ≈ $47.28 Million |
€-8.66 Million ≈ $-10.12 Million |
-0.214x | -200.52% |
| 2010-12-31 | €44.29 Million ≈ $51.78 Million |
€-3.15 Million ≈ $-3.69 Million |
-0.071x | -270.86% |
| 2009-12-31 | €22.53 Million ≈ $26.34 Million |
€939.00K ≈ $1.10 Million |
0.042x | +162.04% |
| 2008-12-31 | €27.42 Million ≈ $32.05 Million |
€-1.84 Million ≈ $-2.15 Million |
-0.067x | +45.33% |
| 2007-12-31 | €29.01 Million ≈ $33.92 Million |
€-3.56 Million ≈ $-4.17 Million |
-0.123x | +79.07% |
| 2006-12-31 | €4.66 Million ≈ $5.45 Million |
€-2.73 Million ≈ $-3.20 Million |
-0.587x | -511.87% |
| 2005-12-31 | €4.78 Million ≈ $5.59 Million |
€681.00K ≈ $796.16K |
0.143x | -- |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more